Management Change/Compensation (Form 8-K)

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(a)(b) On April 1, 2026, Mark Hilz, Chief Operating Officer, Corporate Secretary and member of the Board of Directors of HeartSciences Inc. (the "Company") passed away at the age of 67, following a period of illness. Mr. Hilz served as a member of the Company's Board of Directors since 2013 and as its Chief Operating Officer and Corporate Secretary since March 2022.

The Company mourns the loss of Mr. Hilz, an esteemed colleague, visionary and friend, and extends its sincere condolences to his family and loved ones.

As the MyoVista Insights™ software platform has now been launched and the MyoVista® wavECG™ has been submitted for the U.S. Food and Drug Administration ("FDA") clearance, the Company does not anticipate hiring a new Chief Operating Officer or replacing the role in the foreseeable future. The Company does not anticipate any changes to its business, operations or planned commercialization of the MyoVista Insights platform, including its MyoVista® wavECG™ device submission to the FDA originally submitted to the FDA in December 2025 for 510(k) premarket clearance, as a result of Mr. Hilz's passing.